Monitor the Phase 3 APOLLO study completion in March 2026 and topline data expected in Q4 2026 for bitopertin, as well as the FDA response to the CRL. The strong cash position provides runway but the increasing expenses and regulatory setback could pressure the stock.
IRON drugs
IRON drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 26 $67.91entry
- T+1 · 9mo ago −1.90%α −1.45% · $66.62
- T+5 · 9mo ago −11.15%α −10.02% · $60.34
- T+20 · 8mo ago −8.69%α −2.29% · $62.01
- T+60 · 6mo ago −1.15%α −8.90% · $67.13
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Disc Medicine reported a significant increase in net loss to $212.2 million in 2025, primarily due to higher R&D and SG&A expenses. Despite receiving a Complete Response Letter (CRL) from the FDA for bitopertin, the company maintains a strong cash position of $791.2 million, providing runway into 2029. The company is advancing its pipeline with positive data from DISC-0974 in myelofibrosis and progressing other clinical trials.
Key Financial Metrics
Key Facts
- Net loss increased to $212.2 million in 2025 from $109.4 million in 2024
- Received Complete Response Letter (CRL) from FDA for bitopertin in EPP
- Cash position is $791.2 million, providing runway into 2029
- R&D expenses increased to $170.6 million from $96.7 million
- SG&A expenses increased to $65.4 million from $33.0 million
Financial Impact
Net loss increased by 93.9% to $212.2 million, R&D expenses up 76.4% to $170.6 million, SG&A expenses up 97.6% to $65.4 million
Risk Factors
- FDA may not approve bitopertin after the CRL
- Continued high R&D and SG&A expenses could deplete cash faster than expected
- Clinical trial results may not meet expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-073594 |
| Document: iron-20260226.htm | 0001193125-26-073594 |
| Document: 0001193125-26-073594-index-headers.html | 0001193125-26-073594 |
| Document: 0001193125-26-073594-index.html | 0001193125-26-073594 |
| Document: 0001193125-26-073594.txt | 0001193125-26-073594 |
Track record
43 reports on IRON
6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 10 of 15 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
- Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
- Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
- Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers